Expression pattern of statistically significantly differentially expressed immune-related genes in CL patients compared to healthy volunteers. by Nasrin Masoudzadeh (20300511)

“…<p>(a) A heatmap displaying color-coded expression levels of genes in CL patients from Morocco (MA1-MA14) and Iran (IR1-IR16) infected with <i>L. major</i> and <i>L. tropica</i>, respectively, as well as healthy samples from each group (MAH1-MAH4; IRH1-IRH6). …”

Determinants of institutional delivery for women who had a live birth one year before the survey, NDHS 2022. by Resham B. Khatri (10949429)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Binding affinity of Akt1/Akt2-IN-1, Capivasertib, and Ipatasertib with AKT2 (wild and mutants) protein. by Sadia Afrin Runa (22504971)

Subjects:

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

Subjects:

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

Subjects:

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Raw FCS data for FC_cd73_adsc1. by Parisa Afzal Haghjoo (22453647)

Subjects:

The aging parameters of each group of batteries. by Peijian Jin (22265437)

Subjects:

Minimal data set. by Peijian Jin (22265437)

Subjects:

Battery parameters. by Peijian Jin (22265437)

Subjects: